Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002383 · ClinicalTrials.gov registry record · Phase 1
A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00002383 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 80 participants.
The verdict
NCT00002383, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
To compare the antiviral activity, safety, and pharmacokinetics of saquinavir hard gel capsule (HGC) formulation, to 1 of 3 doses of saquinavir soft gel capsule (SGC) formulation administered orally every 8 hours for 4 weeks.
Interventions
- DRUG Saquinavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002383
The ClinicalTrials.gov registry entry for NCT00002383 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Saquinavir is the first listed.
NCT00002383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002383 about?
NCT00002383 is a clinical study titled "A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients". To compare the antiviral activity, safety, and pharmacokinetics of saquinavir hard gel capsule (HGC) formulation, to 1 of 3 doses of saquinavir soft gel capsule (SGC) formulation administered orally every 8 hours for 4 weeks.
What is the current status of trial NCT00002383?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants.
What interventions are being tested in trial NCT00002383?
The interventions under investigation include: Saquinavir (DRUG).
Who is sponsoring clinical trial NCT00002383?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.